Chardan Capital Issues Pessimistic Forecast for SAB Biotherapeutics (NASDAQ:SABS) Stock Price

SAB Biotherapeutics (NASDAQ:SABS) had its price objective reduced by equities research analysts at Chardan Capital from $25.00 to $20.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of SAB Biotherapeutics in a research report on Tuesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Buy” and an average price target of $11.40.

SAB Biotherapeutics Stock Up 1.6 %

Shares of SABS stock opened at $1.25 on Tuesday. The business has a 50 day moving average of $1.89 and a two-hundred day moving average of $2.81. SAB Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $5.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Friday, March 28th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.07). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.12 million. As a group, equities analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

Institutional investors have recently made changes to their positions in the stock. HB Wealth Management LLC raised its holdings in SAB Biotherapeutics by 118.6% during the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after purchasing an additional 128,800 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at $52,000. Northern Trust Corp bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth $43,000. Geode Capital Management LLC lifted its holdings in shares of SAB Biotherapeutics by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after buying an additional 12,692 shares during the period. Finally, Diadema Partners LP bought a new position in SAB Biotherapeutics during the fourth quarter valued at about $114,000. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.